Exenatide vs Semaglutide

Exenatide is a GLP-1 receptor agonist sold under the brand names Byetta and Bydureon, and it is FDA-approved only for treating type 2 diabetes. Semaglutide is also a GLP-1 receptor agonist, but it is sold as Ozempic, Wegovy, and Rybelsus, and it is FDA-approved for type 2 diabetes, obesity, chronic kidney disease, and reducing cardiovascular risk.

AI summary of the sources below.